Here, we focus on the expression levels of MCT1 and CD163 on macrophages in breast cancer specimens to investigate the correlation between the expression of MCT1 on macrophages, macrophage phenotypes, and survival outcomes to explore the impact of tumor metabolic reprogramming on the remodeling of the immune microenvironment. Here, SLC16A1 is linked to breast cancer.